This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Cortex has inactivated but hasn't formerly withdrawn the IND while it reviews the FDA response but said any resubmission for ADHD is unlikely. The company is also studying CX717 for acute treatment of respiratory depression and for Alzheimer's Disease. Cortex noted that an acute indication requiring a lower dose or an indication with a different risk/benefit profile would be a better fit for the drug. Shares tumbled $1.14, or 63%, to 66 cents.

On the rising side, Novacea (NOVC) edged up 11 cents, or 1.7%, to $8.60, after initiating a phase II, 56-patient trial for banoxantrone, an investigational anti-cancer prodrug in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), a type of cancer that starts with white blood cells in the bone marrow.

The primary efficacy objective is the response rate over three cycles of the drug, and the secondary efficacy objectives are duration of response and overall survival. The study will also evaluate safety and tolerability.

Also, Momenta (MNTA - Get Report) climbed after disclosing top-line results from a phase I study and announcing that it treated the first patient in its phase II study (called the Eminence trial) on the IV formulation of its blood thinner M118. The study is designed to treat patients with stable coronary artery disease who are undergoing percutaneous coronary intervention (PCI). Shares rose 63 cents, or 5%, to $13.08.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
NOVC $0.28 -1.75%
ARIA $8.92 -0.50%
COR $47.28 -0.51%
MNTA $21.36 1.30%
NPSP $45.97 0.02%

Markets

DOW 18,076.27 +64.33 0.36%
S&P 500 2,114.07 +4.47 0.21%
NASDAQ 5,099.2310 +22.7070 0.45%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs